Navigation Links
BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life'
Date:7/7/2008

FREDERICK, Md., July 7 /PRNewswire-FirstCall/ -- ActiPatch(TM), the product marketed by Bioelectronics Corp. (Pink Sheets: BIEL), is changing the face of medicine and the way we heal. Recently chosen as "One of 9 Medical Breakthroughs That May Change Your Life," by MedicalHeadway.com, ActiPatch is fast becoming the treatment of choice for everything from soft tissue injuries to surgical recovery.

"The decision to include ActiPatch in the top 9 medical breakthroughs was an easy one," said Reginald Saxton, President of Medical Headway. "ActiPatch fills the void created by consumers who would rather not take pain medications and are seeking safe and effective alternative treatment options," Saxton added, "I knew our readers would be very interested in this product for that reason".

ActiPatch is a drug-free wafer thin patch with an embedded battery operated microchip that delivers weeks of continuous pulsed RF therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, home use method that reduces soft tissue pain and swelling, and accelerates healing.

When using ActiPatch, bruises that would normally take three weeks to heal often heal in a week; ankle sprains usually respond positively with reduced pain and swelling in only a single day; plastic surgery incisions that would normally take weeks to heal typically heal in less than a week. These claims are supported by multiple clinical trials and strong endorsements from leading surgeons and physicians.

BioElectronics has already received FDA clearance for one surgical procedure, (blepharoplasty), and is now able to sell the product within the United States through physician referral. In addition, BioElectronics has received blanket approval in the European Union, Canada, and dozens of countries. These international approvals have allowed the product to be placed in stores for over-the-counter purchase outside the United States.

Andrew J. Whelan, CEO of BioElectronics Corporation, explains, "ActiPatch with its non-invasive, very efficient treatment for swelling and pain while accelerating recovery is the medicine of the future available today. We are actively pursuing additional reimbursement approvals nationally. ActiPatch is an important product that not only works without side-effects, it also has the potential to help keep medical costs down at a time when they appear to be spiraling out of control," adds Whelan.

MedicalHeadway.com is an online medical breakthrough library published by Medical Headway, LLC of Houston, TX. Dedicated to arming the public with news of the latest breakthroughs in the world of medicine, the company offers consumers free and complete access to its growing library of cutting-edge, professional medical treatment and product information. "In our opinion, ActiPatch is a huge advance for millions of people who would rather not take a pill or who need faster pain relief ... a clear breakthrough everyone should know about," explains Saxton.

For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.

Information on ActiPatch and BioElectronics Corporation is available at the following websites:

-- U.S. Consumer: http://www.actipatchonline.com

-- Podiatry: http://www.pemfpodiatry.com

-- Plastic Surgery: http://www.plasticsurgeryrelief.com and

http://www.makemeheal.com

-- German orthopedic foot & ankle: http://www.diesfussexperten.de

-- Italy and Switzerland: http://www.actipatch.it

-- Canada: http://www.actipatchpaintherapy.ca

-- Netherlands: http://www.actipatch.de

-- Singapore & Malaysia: http://www.astonixlife.com

-- BioElectronics Corp: http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Media Relations Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email: pbaker@bigpictureagency.com

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email: jnoel701@yahoo.com


'/>"/>
SOURCE Bioelectronics Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
2. BioElectronics Announces Conference Call to Update Investors on Growth Initiatives
3. BioElectronics Corporation Receives Major Orders From Italian Distributor
4. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
5. BioElectronics Announces Canadian Retail Product Launch
6. BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
9. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
10. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
11. Neogen Acquires Product Line From DuPont Animal Health Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
(Date:2/16/2017)... (PRWEB) , ... February 16, ... ... Albany Molecular Research Inc. has further extended its industry leading Biochemistry Services ... service offers state-of-the-art cGMP techniques and methods for the biochemical and ...
(Date:2/15/2017)... CA (PRWEB) , ... February 15, 2017 , ... ... that Park SmartScan, a powerful AFM operating software that drastically boosts productivity with single ... completely automatizes all of the functions of setting up and taking the image once ...
(Date:2/15/2017)... , Feb. 15, 2017  NASA provider SpaceX is ... to the  International Space Station  no earlier than 10:01 ... launch will begin at 8:30 a.m. on NASA Television ... Dragon spacecraft will lift off on the company,s ... Kennedy Space Center in ...
Breaking Biology Technology:
(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
(Date:2/8/2017)... LONDON , Feb. 7, 2017 Report ... $12.5 billion by 2021 from $8.3 billion in 2016 ... from 2016 to 2021. Report Includes - An ... of global market trends, with data from 2015 and ... through 2021. - Segmentation of the market on the ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):